It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A quick guide outlining which cryptocurrency to buy first, focusing on accessibility, liquidity, and practical use cases for newcomers.
24,236 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Bitcoin holds a narrow path near the $64,000 level as Michael Saylor drops another orange dot hint, reigniting debate...
Fresh analyst notes Thursday spark upgrades across Alphabet, Meta, Palo Alto Networks and more, signaling growing opt...
Tilray Brands is set to report on July 28. This article breaks down whether should tilray brands stock be on your rad...
Lucid faces a pivotal year as production scales and capital needs rise. This guide outlines plausible paths for where...
When a big investor exits a biotech stock, it rattles the market and raises questions. This deep dive explains the 'f...
Retail investors are increasingly offered access to private-market products as Wall Street courts Main Street. But ex...
Prediction-market odds now place bitcoin's year-end odds reaching 10%. This article breaks down what that means for y...
A Kalshi insider-trading probe sparks headlines about a captivating, hypothetical scenario: a mrbeast video editor fi...
Prediction markets are pricing a surprisingly small cost for a big Bitcoin bet. This article explains what traders pa...
A big stock move and a buyout rumor are reshaping how traders view NCR Atleos. A large block sale drew attention, jus...
Two months can change a market outlook dramatically. This piece breaks down why the idea of an opinion: stock market ...